Abstract: Provided are a CD80 protein variant and a fusion protein comprising the CD80 protein variant, which can bind to PD-L1, CTLA-4 and CD28, activate the activity of T lymphocytes, and inhibit the growth and/or proliferation of tumors or tumor cells. Also provided are a nucleic acid encoding the fusion protein, a vector comprising the fusion protein, a cell comprising the nucleic acid or the vector, a method for preparing the fusion protein, and use of the fusion protein.

Abstract: Provided is a SIRP? variant and a fusion protein thereof, capable of specifically blocking interaction between CD47 protein and SIRP?, not causing coagulation reaction, and capable of inhibiting growth and/or proliferation of tumors or tumor cells.

Abstract: The present application relates to a bifunctional fusion protein, which includes a first binding domain that specifically binds to CLDN18.2, and a second binding domain that specifically binds to a CD47 protein, wherein the second binding domain has at least one of the following characteristics: (a) binding to a CD47 protein at 4×10?8M or a lower KD value; (b) specifically blocking the interaction between CD47 protein and SIRP?; (c) not causing a coagulation reaction; and (d) inhibiting the growth and/or proliferation of a tumor or tumor cells.

Abstract: A bispecific fusion protein may include a first binding domain and a second binding domain. The first binding domain may include an antibody specifically binding to PD-L1, the antibody may include two antibody light chains and two antibody heavy chains, and the antibody light chains and the antibody heavy chains may be linked by disulfide bonds. The second binding domain may include an Ig-like domain of VEGFR1 and an Ig-like domain of VEGFR2. The N-terminus of the Ig-like domain of VEGFR1 or the N-terminus of the Ig-like domain of VEGFR2 may be directly or indirectly linked to the C-terminus of the antibody heavy chains, separately. A pharmaceutical composition may include the bispecific fusion protein. Such a bispecific fusion protein may be pharmaceutically used and may effectively and safely kill tumor cells.

Abstract: Provided is an antibody or an antigen-binding fragment thereof, having one or more properties selected from the group consisting of: 1) being capable of binding to an AXL protein by a KD value of 1×10?8 M or lower; 2) being capable of specifically recognizing an AXL protein expressed on a cell surface; and 3) being capable of mediating internalization after binding to the AXL protein expressed on the cell surface. The antibody may further used for constructing an immunoconjugate. The antibody and the immunoconjugate may inhibit the proliferation of tumor cells.

Abstract: Provided by the present invention are a fusion protein binding to a CD47 protein and an application thereof, wherein the fusion protein is capable of binding to a CD47 protein by using a KD value of 1×10?8M or lower. The fusion protein may specifically block the interaction between a CD47 protein and SIRP? without causing a blood coagulation reaction, and may further inhibit the growth and/or proliferation of tumors or tumor cells.

Abstract: Provided by the invention is an antibody or an antigen-binding fragment thereof, which binds to a CD38 protein at a KD value below 1×10?9M. The antibody or an antigen-binding fragment thereof has strong specific recognition and binding capabilities for CD38 protein, and may kill CD38+ cells by means of antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and/or apoptosis. Further provided by the present invention is an application of the antibody or antigen-binding fragment thereof in preventing and treating tumors.

Abstract: Provided by the invention is an antibody or an antigen-binding fragment thereof, which binds to a CD38 protein at a KD value below 1×10-9M. The antibody or an antigen-binding fragment thereof has strong specific recognition and binding capabilities for CD38 protein, and may kill CD38+ cells by means of antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and/or apoptosis. Further provided by the present invention is an application of the antibody or antigen-binding fragment thereof in preventing and treating tumors.

Abstract: Provided is a separated antigen binding protein, containing at least one CDR in VH with the amino acid sequence as shown in SEQ ID NO: 1 or SEQ ID NO: 46; and at least one CDR in VL with the amino acid sequence as shown in SEQ ID NO: 2. Also provided are an immunoconjugate containing the separated antigen binding protein, nucleic acid coding the separated antigen binding protein, a carrier containing the separated antigen binding protein, a cell containing the nucleic acid or the carrier, a method for preparing the separated antigen binding protein, and use of the separated antigen binding protein.

Abstract: Provided is an antibody or an antigen-binding fragment thereof having one or more properties selected from the group consisting of: 1) capable of binding to a BCMA protein with a KD value of 1.8×10?9 M or lower; 2) capable of specifically recognizing a BCMA protein expressed on cell surfaces; 3) capable of being internalized by cells; and 4) capable of inhibiting tumors and/or tumor cell proliferation. The antibody can also be used to construct immunoconjugates. The antibody and immunoconjugates can all prevent or treat tumors.

Abstract: Provided are a fusion protein, and an immunoconjugate, a nucleic acid molecule, a carrier, a composition, a cell and a preparation method related thereto, for treating tumors and/or autoimmune diseases.

Abstract: Provided is a fusion protein, comprising a first binding domain that specifically binds a tumor-associated antigen, and a second binding domain that specifically binds a CD47 protein, wherein the second binding domain comprises a mutant of a human SIRP? variant 1. Also provided are an immunoconjugate, nucleic acid molecules, vectors, compositions, and cells related to the fusion protein and preparation methods therefor, and the uses thereof in the preparation of medicaments.

Abstract: Provided is an antibody or an antigen-binding fragment thereof, having one or more properties selected from the group consisting of: 1) being capable of binding to an AXL protein by a KD value of 1×10?8M or lower; 2) being capable of specifically recognizing an AXL protein expressed on a cell surface; and 3) being capable of mediating internalization after binding to the AXL protein expressed on the cell surface. The antibody may further used for constructing an immunoconjugate. The antibody and the immunoconjugate may inhibit the proliferation of tumor cells.

Abstract: Provided by the present invention are a fusion protein binding to a CD47 protein and an application thereof, wherein the fusion protein is capable of binding to a CD47 protein by using a KD value of 1×10?8M or lower. The fusion protein may specifically block the interaction between a CD47 protein and SIRP? without causing a blood coagulation reaction, and may further inhibit the growth and/or proliferation of tumors or tumor cells.

Abstract: Provided by the invention is an antibody or an antigen-binding fragment thereof, which binds to a CD38 protein at a KD value below 1×10-9M. The antibody or an antigen-binding fragment thereof has strong specific recognition and binding capabilities for CD38 protein, and may kill CD38+ cells by means of antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and/or apoptosis. Further provided by the present invention is an application of the antibody or antigen-binding fragment thereof in preventing and treating tumors.